Revenue: As of FY2025 Q2, the actual value is USD 0.EPS: As of FY2025 Q2, the actual value is USD -0.01.<h3>Segment Revenue</h3><ul><li>Sales of Products and Services: $0 for the three months ended June 30, 2025, and $0 for the same period in 2024. For the six months ended June 30, 2025, sales were $0 compared to $3,488 for the same period in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: $249,722 for the three months ended June 30, 2025, compared to $598,348 for the same period in 2024. For the six months ended June 30, 2025, net loss was $592,136 compared to $1,007,853 for the same period in 2024.</li><li>Operating Expenses: $249,699 for the three months ended June 30, 2025, compared to $470,436 for the same period in 2024. For the six months ended June 30, 2025, operating expenses were $592,094 compared to $882,518 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: - $354,994 for the six months ended June 30, 2025, compared to - $758,342 for the same period in 2024.</li><li>Net Cash Provided by Investing Activities: $79,904 for the six months ended June 30, 2025, compared to $81,963 for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: $473,919 for the six months ended June 30, 2025, compared to $718,314 for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to continue focusing on its core business of stem cell research and development, with an emphasis on building the first public endometrial stem cell repository in the world. The company aims to expand its product offerings under the VIVCELL brand, including healthcare products and stem cell-related services.</li><li>Non-Core Business: There are no specific plans mentioned for non-core business segments or divestitures in the report.</li></ul>

Yubo International Biotech Limited | 10-Q: FY2025 Q2 Revenue: USD 0